Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...

H.C. Wainwright reiterated its Buy rating and $75.00 price target for the company, citing promising data from the Western study of CRB-701, a nectin-4 antibody-drug conjugate. The study showed no ...

This follows the presentation of updated data from Corbus' Western study of CRB-701 at the American Society of Clinical Oncology Genitourinary symposium, which showcased a favorable risk-benefit ...

It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price ...

You are responsible for reading, understanding, and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.